ArticleBMC medical genomics2026
A founder variant in TANGO2 p.(Leu148Trp) in ten Palestinian families: clinical characterization and haplotype analysis of TANGO2 deficiency disorder.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTANGO2 deficiency disorder (TDD) is a rare autosomal recessive condition characterized by recurrent metabolic crises, rhabdomyolysis, encephalopathy, seizures, intellectual disability, and life-threatening cardiac arrhythmias.
methodsHere, we describe 16 affected individuals from 10 consanguineous Palestinian families harboring a shared homozygous missense variant in TANGO2 (NM_152906.7:c.443T > G; NP_690870.3:p.(Leu148Trp)). Exome sequencing identified the variant in three probands and targeted Sanger sequencing confirmed segregation in all remaining families. The variant is absent from population databases and is predicted to be deleterious by multiple in silico tools. Microsatellite marker analysis was performed using five short tandem repeat (STR) markers spanning the TANGO2 locus.
resultsClinical presentation was heterogeneous, including developmental delay, recurrent encephalopathy, rhabdomyolysis, seizures, and cardiac involvement. Microsatellite marker analysis revealed a conserved ancestral haplotype flanking the TANGO2 locus in all genotyped affected individuals, supporting a founder effect in this population. Supportive management including coenzyme Q10 and B-complex vitamins (B-100) was commonly used; consistent with prior reports, some families described reduced frequency and/or severity of spells following supplementation.
conclusionsThese findings provide strong clinical, genetic, and haplotype evidence supporting reclassification of the TANGO2 p.(Leu148Trp) variant as likely pathogenic and highlight the importance of early molecular diagnosis and targeted screening strategies in high-consanguinity populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.